Reply

Authors :: Vedran Pavlovic
Edward Gane
Ben Fillippo Krippendorff
Joseph F. Grippo
S Ottosen
Cynthia Wat
Man-Fung Yuen
Henrik Mueller
Source :: Hepatology. 75:1050-1051
Publication Year :: 2021
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2021.
Abstract: Firstly, Dr Vaillant proposes RO7062931 should have exhibited greater HBsAg reductions, given the efficient RO7062931 liver uptake, rapid turnover of HBsAg, and rapid protein reductions observed with GalNAc-ASOs in other therapeutic indications. We find this reasoning unsatisfactory, primarily as there should be no expectations of similar potency for GalNAc-ASOs targeting different mRNA species.